weight gain after glp 1 Trajectory of regain cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression New study finds rapid weight
Description
6 that diabetes and obesity treatment drug sales increased 16% YoY

Patients were excluded if they had a prescription fill within 60 days after the date of discontinuation or if the GLP-1 RA indication (AOM or ADM) could not be determined

In these patients, especially those with heart or kidney disease, the drugs improved blood sugar control, reduced the risk of heart and kidney complications, supported weight loss, and lowered the risk of early death

In addition, AOPPs upregulate the Wnt/-catenin pathway through the receptor for advanced glycation end-products (RAGE) receptor, contributing to podocyte dysfunction [60]
Summary GLP-1 RA originally emerged as drugs for the treatment of hyperglycemia and are currently licensed for the management of T2D and/or overweight/obesity

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist, which means it mimics a naturally occurring hormone that helps regulate both blood sugar and appetite